Japan Vaccine Market Size & Outlook, 2026-2033

The vaccine market in Japan is expected to reach a projected revenue of US$ 5,728.3 million by 2033. A compound annual growth rate of 5.7% is expected of Japan vaccine market from 2026 to 2033.
Revenue, 2025 (US$M)
$3,619.9
Forecast, 2033 (US$M)
$5,728.3
CAGR, 2026 - 2033
5.7%
Report Coverage
Japan

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan vaccine market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Japan vaccine market highlights

  • The Japan vaccine market generated a revenue of USD 3,619.9 million in 2025 and is expected to reach USD 5,728.3 million by 2033.
  • The Japan market is expected to grow at a CAGR of 5.7% from 2026 to 2033.
  • In terms of segment, viral vaccines was the largest revenue generating indication in 2025.
  • Other Indication is the most lucrative indication segment registering the fastest growth during the forecast period.


Vaccine market data book summary

Market revenue in 2025USD 3,619.9 million
Market revenue in 2033USD 5,728.3 million
Growth rate5.7% (CAGR from 2026 to 2033)
Largest segmentViral vaccines
Fastest growing segmentOther Indication
Historical data2021 - 2024
Base year2025
Forecast period2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationViral Vaccines, Bacterial Vaccines, Cancer Vaccines, Allergy Vaccines, Other Indication
Key market players worldwideSerum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc


Other key industry trends

  • In terms of revenue, Japan accounted for 5.0% of the global vaccine market in 2025.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, China vaccine market is projected to lead the regional market in terms of revenue in 2033.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 5,198.2 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Vaccine Market Scope

Vaccine market segmentation & scope

Vaccine Market Companies

Name Profile # Employees HQ Website
Moderna Inc View profile 5600 200 Technology Square, Cambridge, MA, United States, 02139 https://www.modernatx.com
BioNTech SE ADR View profile 6133 An der Goldgrube 12, Mainz, RP, Germany, D-55131 https://www.biontech.de
CSL Ltd View profile 32000 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 https://www.csl.com
Sinovac Biotech Ltd View profile 3261 No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 http://www.sinovac.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
Serum Institute of India Pvt. Ltd. View profile 1001-5000 Pune, Maharashtra, India, Asia http://www.seruminstitute.com/
GSK PLC View profile 70200 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS https://www.gsk.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com

Japan vaccine market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine market will help companies and investors design strategic landscapes.


Viral vaccines was the largest segment with a revenue share of 64.8% in 2025. Horizon Databook has segmented the Japan vaccine market based on viral vaccines, bacterial vaccines, cancer vaccines, allergy vaccines, other indication covering the revenue growth of each sub-segment from 2021 to 2033.


Japan is one of the most technologically advanced countries in Asia Pacific. Its influenza vaccine market is expected to grow rapidly over the forecast period owing to high government spending for reducing the flu burden.

Multiple initiatives, such as government grants to various research institutes and companies, can help develop practical solutions for the influenza burden in the country. In October 2022, Japan announced an investment of USD 2 billion in a research initiative to boost vaccine R&D in the country.

Similarly, in October 2022, the Government of Japan started preparations against flu and COVID-19. As per these preparations, the government recommends people get vaccinated against the flu if they notice any symptoms. Furthermore, several organic and inorganic initiatives undertaken by leading participants to strengthen their presence are driving the country’s market.

Reasons to subscribe to Japan vaccine market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan vaccine market databook

  • Our clientele includes a mix of vaccine market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan vaccine market , including forecasts for subscribers. This country databook contains high-level insights into Japan vaccine market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan Recombinant Vaccines - Vaccine Market, 2024 - 2030 (US$M)

Japan Vaccine Market Outlook Share, 2025 & 2033 (US$M)

Japan Recombinant Vaccines - Vaccine Market, 2024 - 2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online